NCT04675424

Using Artificial Intelligence (AI)-Assisted Pulse Diagnosis Analysis on Precision Critical Medicine.

Completed Last updated 21 September 2023

What this trial tests

trial testing ANSwatch in ICU Patients in 45 participants. Completed in 6 October 2022.

Timeline

15 November 2020

Primary endpoint
6 September 2022

6 October 2022

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	45
Start date	15 November 2020
Primary completion	6 September 2022
Estimated completion	6 October 2022
Sites	1 location across Taiwan

Drugs / interventions tested

• ANSwatch

Conditions studied

• ICU Patients — all drugs for ICU Patients →
• Shock — all drugs for Shock →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 20 to 80, any sex, with ICU Patients or Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Precision/personalized medicine becomes an important part of modern medical system in the recent years. In the past, the treatments for patients have been decided by doctors according patients' symptoms and/or regular biochemical profiles. However, it is not uncommon that patients' condition varies tremendously even they have same diagnosis, and under such condition, treatment efficacy may be limited due to the heterogeneity among patients. Therefore, lack of therapeutic efficacy may be not really ineffective, and the main reason may be inadequate patient classification. For this reason, the "omics"-based personal/precision medicine emerges recently and becomes more and more important. However, in contrast to feasible and common "personalized" medicine, the approach of precision medicine to the molecular medicine level is still difficult, especially among patients in intensive critical units (ICUs). In contrast to cancer, which has remarkable advances in the past decades, the precision/personal medicine is more difficult in critical and emergent medicine. One reason is the amount of omics data is quite huge and thus dealing with omics data is time consuming. Therefore, it is not effective in daily clinical practice in ICUs care. For this condition, the investigators propose that the combination of clinical data, including pulse diagnosis by traditional Chinese medicine (TCM) doctor or ANSwatch wrist sphygmomanometer, fluid responsiveness by "Masimo" Radical-7 Pulse CO-Oximeter, and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. There are two main goals for this study: (1) After establishing clinical traditional Chinese medicine (TCM) pulse diagnosis and ICU clinical parameters databases, acquiring and features of pulse diagnosis by applying AI and (2) analyzing the correlations between the features of pulse diagnosis and important clinical parameters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.